⌕

Argen X (ARGX) vs BeOne Medicines (ONC)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
74
Argen X SE
$960.04 · $59B · as of last close
Best returnsCalmest rideHighest quality
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is total return.

#2 FIT
63
BeOne Medicines Ltd
$416.54 · $48B · as of last close

The challenger. Trails the leader on the balanced score. Its widest win over the field is valuation.

ARGX edges ahead (74/100 vs ONC 63) under a balanced style, mostly on total return. But ONC wins on valuation, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorARGXONC
Overall fit score
weighted for your balanced goal
✓ 74
63
Valuation
Cheaper for what you get
1×
P/E 46 · EV/EBITDA 53.5
P/E fiscal 2025
14
✓ P/E 52 · EV/EBITDA 33.8
P/E trailing
26
P/E bases differ: fiscal 2025 for ARGX, trailing for ONC.
Growth
Revenue & earnings momentum
1×
✓ —
99
—
88
Profitability & quality
Margins & return on capital
1×
✓ Net 30% · ROIC 100%
fiscal 2025
94
Net 14% · ROIC 14%
TTM through Sep 30, 2026
77
Total return
Share-price change with dividends reinvested
1×
✓ 5Y +25%/yr
87
5Y +3%/yr
56
Risk (calm = better)
Volatility & drawdown
1×
✓ β 0.5 · DD −38%
82
β 0.6 · DD −69%
64
Balance sheet†
Debt vs cash cushion
1×
✓ Net debt/EBITDA −3.0×
fiscal 2025
78
Net debt/EBITDA −3.7×
TTM through Sep 30, 2026
65
Dividend & income
Cash paid to you
1×
✓ —
40
✓ —
40
Analyst sentiment
Forward EPS growth (consensus)
1×
✓ Est EPS +36%/yr · 9 analysts
100
Est EPS +24%/yr · 11 analysts
86
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ ARGX■ ONC
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
ARGX−38%0.5540%5Y
ONC−69%0.6054%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on total return: 5Y +25%/yr (score 87).

▲ Leads on risk (calm = better): β 0.5 · DD −38% (score 82).

BEAR CASE

▼ Weakest on valuation: P/E 46 · EV/EBITDA 53.5 (score 14).

BULL CASE

▲ Best factor is growth: — (score 88).

BEAR CASE

▼ Weakest on total return: 5Y +3%/yr (score 56).

▼ Weakest on risk (calm = better): β 0.6 · DD −69% (score 64).

WHAT COULD CHANGE THE SCORE
ValuationCurrently 14/100 (P/E 46 · EV/EBITDA 53.5). Taking it to 100 would lift the balanced score by 11 points, the biggest single move available.
Dividend & incomeCurrently 40/100 (—). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
ValuationCurrently 26/100 (P/E 52 · EV/EBITDA 33.8). Taking it to 100 would lift the balanced score by 9 points, the biggest single move available.
Dividend & incomeCurrently 40/100 (—). Taking it to 100 would lift the balanced score by 7 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.